Efficacy and Safety of the Anti-mucosal Addressin Cell Adhesion Molecule-1 Antibody Ontamalimab in Patients with Moderate-to-Severe Ulcerative Colitis or Crohn's Disease.

21 , 22 In patients with moderate-to-severe CD, ontamalimab was well tolerated, but clinical endpoint differences did not reach statistical significance compared with placebo. 23 , 24 Here, we present the results from three phase 3 randomised controlled studies evaluating the efficacy and safety of ontamalimab for the induction and maintenance of remission in patients with moderate-to-severe UC.

also in 111,027 other papers